IP Library Granted Patent US 7,629,146
Granted Patent B2
US 7,629,146 · App. 11/544,970 · Granted Dec 8, 2009

Truncated 24kDa basic fibroblast growth factor

Assignee: The Scripps Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,629,146
App. No.
11/544,970
Granted
Dec 8, 2009
Kind
B2
Abstract

The invention relates to fragments of an amino acid sequence of mature, full length 24 kDa fibroblast growth factor- 2 or an analog thereof. The fragments have an activity that inhibits the migration of cultured cells as well as inhibiting angiogenesis, tumor growth, or any other processes that involve the migration of cells in vivo. This fragment does not stimulate the proliferation of cells which is in contrast to activity shown by the mature, full-length 24 kDa fibroblast growth factor- 2 . The present invention also relates to a DNA molecule encoding the fragment, an expression vector and a transformed host containing the DNA molecule, and a method of producing the protein by culturing the transformed host. Moreover, the present invention relates to a therapeutic composition the 24 kDa fibroblast growth factor fragment and a pharmaceutically acceptable carrier.

Claims (11)

1. An isolated nucleic acid molecule comprising the nucleic acid molecule of SEQ ID NO: 5, wherein the nucleic acid molecule encodes for a polypeptide having at least one of anti-angiogenic, tumor suppressive or anti-migratory activity, but does not have stimulation of cell proliferation activity.

2. An isolated nucleic acid molecule 95% identical to SEQ ID NO: 5, wherein the nucleic acid molecule encodes a protein having at least one of anti-angiogenic, tumor suppressive or anti-migratory activity, but does not have stimulation of cell proliferation activity.

3. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid molecule is covalently linked to a detectable group.

4. The isolated nucleic acid molecule of claim 3 , wherein said detectable group is selected from the group consisting of radiolabel and fluorescent group.

5. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid molecule is operably linked to one or more expression control elements.

6. A vector comprising the nucleic acid of claim 1 .

7. A recombinant host cell, comprising the vector of claim 6 , whereby said cell is capable of expressing said nucleic acid.

8. The host cell of claim 7 , wherein said host is selected from the group consisting of prokaryotic and eukaryotic hosts.

9. A process for the production of a polypeptide having at least one of anti-angiogenic, tumor suppressive or anti-migratory activity, but does not have stimulation of cell proliferation activity, said process comprising:

a) growing under suitable nutrient conditions host cell transformed or transfected with the nucleic acid molecule of SEQ ID NO: 5; and

b) isolating the polypeptide products of the expression of the nucleic acid molecule.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 12, 2017
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044846/0150 →
Continuity (3)
Continuation In Part 1040841500 · Apr 7, 2003
Provisional Application 6037021200 · Apr 8, 2002
Related Publication 20080051356A1 · Feb 28, 2008